ES2655656T3 - Biomateriales adecuados para usar como implantes detectables mediante imagen de resonancia magnética, eluyentes de fármacos para oclusión vascular - Google Patents
Biomateriales adecuados para usar como implantes detectables mediante imagen de resonancia magnética, eluyentes de fármacos para oclusión vascular Download PDFInfo
- Publication number
- ES2655656T3 ES2655656T3 ES13794343.7T ES13794343T ES2655656T3 ES 2655656 T3 ES2655656 T3 ES 2655656T3 ES 13794343 T ES13794343 T ES 13794343T ES 2655656 T3 ES2655656 T3 ES 2655656T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- acrylamide
- drug
- iron oxide
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 129
- 239000003814 drug Substances 0.000 title claims abstract description 129
- 239000012620 biological material Substances 0.000 title claims abstract description 87
- 239000007943 implant Substances 0.000 title claims abstract description 40
- 206010053648 Vascular occlusion Diseases 0.000 title claims abstract description 39
- 208000021331 vascular occlusion disease Diseases 0.000 title claims abstract description 39
- 238000002595 magnetic resonance imaging Methods 0.000 title claims abstract description 36
- 239000003480 eluent Substances 0.000 title description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims abstract description 220
- 229920000642 polymer Polymers 0.000 claims abstract description 109
- MVBJSQCJPSRKSW-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]prop-2-enamide Chemical compound OCC(CO)(CO)NC(=O)C=C MVBJSQCJPSRKSW-UHFFFAOYSA-N 0.000 claims abstract description 77
- CYUZOYPRAQASLN-UHFFFAOYSA-N 3-prop-2-enoyloxypropanoic acid Chemical compound OC(=O)CCOC(=O)C=C CYUZOYPRAQASLN-UHFFFAOYSA-N 0.000 claims abstract description 68
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229940047670 sodium acrylate Drugs 0.000 claims abstract description 66
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 claims abstract description 63
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 claims abstract description 58
- 239000002245 particle Substances 0.000 claims abstract description 54
- 239000004005 microsphere Substances 0.000 claims description 169
- 239000000203 mixture Substances 0.000 claims description 139
- 239000000178 monomer Substances 0.000 claims description 118
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 76
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 74
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 claims description 71
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 claims description 49
- 229960004679 doxorubicin Drugs 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 32
- 239000000725 suspension Substances 0.000 claims description 28
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 230000000379 polymerizing effect Effects 0.000 claims description 24
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 23
- 229940044683 chemotherapy drug Drugs 0.000 claims description 22
- 229960004768 irinotecan Drugs 0.000 claims description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 54
- 239000003431 cross linking reagent Substances 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 28
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 21
- 229940048053 acrylate Drugs 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 229920001577 copolymer Polymers 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 14
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 11
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical group O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 11
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 10
- -1 sodium acrylate Chemical compound 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000001033 granulometry Methods 0.000 description 8
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 239000001632 sodium acetate Substances 0.000 description 7
- 235000017281 sodium acetate Nutrition 0.000 description 7
- 239000005662 Paraffin oil Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 5
- 238000010908 decantation Methods 0.000 description 5
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LEJBBGNFPAFPKQ-UHFFFAOYSA-N 2-(2-prop-2-enoyloxyethoxy)ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCOC(=O)C=C LEJBBGNFPAFPKQ-UHFFFAOYSA-N 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000002767 hepatic artery Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- ZODNDDPVCIAZIQ-UHFFFAOYSA-N (2-hydroxy-3-prop-2-enoyloxypropyl) 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)COC(=O)C=C ZODNDDPVCIAZIQ-UHFFFAOYSA-N 0.000 description 2
- YERHJBPPDGHCRJ-UHFFFAOYSA-N 1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one Chemical compound C=CC(=O)N1CCN(C(=O)C=C)CC1 YERHJBPPDGHCRJ-UHFFFAOYSA-N 0.000 description 2
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- ZRKLEAHGBNDKHM-UHFFFAOYSA-N N,n'-diallyl-2,3-dihydroxysuccinamide Chemical compound C=CCNC(=O)C(O)C(O)C(=O)NCC=C ZRKLEAHGBNDKHM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- PSUHXVMFHGPIJX-UHFFFAOYSA-N piperazine prop-2-enoic acid Chemical compound OC(=O)C=C.OC(=O)C=C.C1CNCCN1 PSUHXVMFHGPIJX-UHFFFAOYSA-N 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BRXCDHOLJPJLLT-UHFFFAOYSA-N butane-2-sulfonic acid Chemical compound CCC(C)S(O)(=O)=O BRXCDHOLJPJLLT-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651389P | 2012-05-24 | 2012-05-24 | |
| US201261651389P | 2012-05-24 | ||
| PCT/US2013/042363 WO2013177364A1 (en) | 2012-05-24 | 2013-05-23 | Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655656T3 true ES2655656T3 (es) | 2018-02-21 |
Family
ID=49621771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13794343.7T Active ES2655656T3 (es) | 2012-05-24 | 2013-05-23 | Biomateriales adecuados para usar como implantes detectables mediante imagen de resonancia magnética, eluyentes de fármacos para oclusión vascular |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10695440B2 (enExample) |
| EP (2) | EP3295961B1 (enExample) |
| JP (1) | JP6208749B2 (enExample) |
| BR (1) | BR112014029149A2 (enExample) |
| CA (1) | CA2866896C (enExample) |
| ES (1) | ES2655656T3 (enExample) |
| WO (1) | WO2013177364A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3295961B1 (en) | 2012-05-24 | 2020-04-08 | Biosphere Medical Inc. | Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion |
| CN110279885B (zh) | 2013-09-19 | 2022-07-26 | 泰尔茂株式会社 | 聚合物颗粒 |
| BR112016005768B1 (pt) | 2013-09-19 | 2021-09-21 | Microvention, Inc | Películas de polímero |
| BR112016010067B1 (pt) | 2013-11-08 | 2023-01-10 | Terumo Corporation | Partículas de polímero e métodos de preparação |
| US9907880B2 (en) | 2015-03-26 | 2018-03-06 | Microvention, Inc. | Particles |
| KR102310696B1 (ko) | 2016-09-28 | 2021-10-12 | 테루모 가부시키가이샤 | 색전 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS509858A (enExample) | 1973-06-02 | 1975-01-31 | ||
| JPS6056676B2 (ja) | 1980-07-18 | 1985-12-11 | 日立造船株式会社 | コンクリ−ト複合パネル |
| ATE130517T1 (de) | 1990-08-08 | 1995-12-15 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff. |
| FR2676927B1 (fr) * | 1991-05-29 | 1995-06-23 | Ibf | Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant. |
| US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
| US6315709B1 (en) * | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
| WO2001072281A2 (en) | 2000-03-24 | 2001-10-04 | Biosphere Medical Inc. | Microspheres for active embolization |
| FR2808026B1 (fr) | 2000-04-25 | 2002-06-14 | Alexandre Laurent | Biomateriau a base de polymere hydrophile presentant un signal specifique en imagerie par resonance magnetique et procede de preparation d'un tel biomateriau |
| JP2005053707A (ja) | 2001-07-30 | 2005-03-03 | Kankyo Device Kenkyusho:Kk | 可視光応答性材料の製造方法 |
| US7462366B2 (en) * | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US8012454B2 (en) * | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US20040161466A1 (en) * | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
| JP4909071B2 (ja) * | 2003-03-24 | 2012-04-04 | プルーローメッド， インコーポレイテッド | 逆感熱性ポリマーを使用する一時的な塞栓形成 |
| WO2005044224A2 (en) | 2003-05-02 | 2005-05-19 | Case Western Reserve University | Drug delivery system based on polymer nanoshells |
| AU2005277542B2 (en) * | 2004-08-19 | 2011-11-17 | Covidien Lp | Water-swellable copolymers and articles and coating made therefrom |
| WO2009073193A2 (en) | 2007-12-03 | 2009-06-11 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| GB0807154D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Aston | Intervertebral disc |
| US9115238B2 (en) * | 2009-05-28 | 2015-08-25 | Corning Incorporated | Swellable synthetic microcarriers for culturing cells |
| EP2451488A2 (en) * | 2009-07-07 | 2012-05-16 | Bartling, Sönke | Multimodal visible polymer embolization material |
| EP3295961B1 (en) | 2012-05-24 | 2020-04-08 | Biosphere Medical Inc. | Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion |
-
2013
- 2013-05-23 EP EP17193907.7A patent/EP3295961B1/en active Active
- 2013-05-23 CA CA2866896A patent/CA2866896C/en active Active
- 2013-05-23 ES ES13794343.7T patent/ES2655656T3/es active Active
- 2013-05-23 BR BR112014029149A patent/BR112014029149A2/pt not_active Application Discontinuation
- 2013-05-23 US US13/900,796 patent/US10695440B2/en active Active
- 2013-05-23 WO PCT/US2013/042363 patent/WO2013177364A1/en not_active Ceased
- 2013-05-23 JP JP2015514174A patent/JP6208749B2/ja active Active
- 2013-05-23 EP EP13794343.7A patent/EP2854869B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2854869A4 (en) | 2015-12-30 |
| CA2866896A1 (en) | 2013-11-28 |
| US20130315838A1 (en) | 2013-11-28 |
| JP2015517390A (ja) | 2015-06-22 |
| EP2854869B1 (en) | 2017-11-01 |
| EP2854869A1 (en) | 2015-04-08 |
| WO2013177364A1 (en) | 2013-11-28 |
| BR112014029149A2 (pt) | 2017-06-27 |
| EP3295961A1 (en) | 2018-03-21 |
| JP6208749B2 (ja) | 2017-10-04 |
| EP3295961B1 (en) | 2020-04-08 |
| US10695440B2 (en) | 2020-06-30 |
| CA2866896C (en) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rolfe et al. | Multimodal polymer nanoparticles with combined 19F magnetic resonance and optical detection for tunable, targeted, multimodal imaging in vivo | |
| Qiao et al. | Multi-responsive nanogels containing motifs of ortho ester, oligo (ethylene glycol) and disulfide linkage as carriers of hydrophobic anti-cancer drugs | |
| Mayorova et al. | Endovascular addressing improves the effectiveness of magnetic targeting of drug carrier. Comparison with the conventional administration method | |
| EP1879554B2 (en) | Compositions and methods using microspheres and non-ionic contrast agents | |
| US10434200B2 (en) | Compositions and associated methods for radioisotope-binding microparticles | |
| JP6208749B2 (ja) | 薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料 | |
| ES2361919T3 (es) | Suministro de fármaco a partir de agentes embólicos. | |
| US11845823B2 (en) | Radiopaque monomers, polymers, microspheres, and methods related thereto | |
| US20210177997A1 (en) | Microspheres containing radioactive isotopes and other markers and associated methods | |
| BR112015008245B1 (pt) | Composições poliméricas de tratamento | |
| CN102743768B (zh) | 肿瘤早期诊断用隐形造影材料及其制备方法 | |
| Qiu et al. | Synthesis and characterization of magnetic polyvinyl alcohol (PVA) hydrogel microspheres for the embolization of blood vessel | |
| JP2022046815A (ja) | 粒子を含むエマルジョン | |
| US20200397766A1 (en) | Porous embolization microspheres comprising drugs | |
| CN113209355B (zh) | 用于实体瘤治疗的可生物降解的药物洗脱微球 | |
| Guisasola et al. | Magnetically responsive polymers for drug delivery applications | |
| Saltzman | Interstitial transport in the brain: principles for local drug delivery | |
| Kakar et al. | Magnetic microspheres: An Overview | |
| ES2735638A1 (es) | Copolimeros y terpolimeros acrilicos funcionales autoasociados y su uso como vehiculos de compuestos bioactivos | |
| Jensen et al. | 03: 18 PM Abstract No. 385 Radiopaque silk-elastinlike protein polymer-based embolic | |
| Oleshchuk | Biodegradable Nanogels from Biocompatible Polymer Precursors | |
| CN120919082A (zh) | 一种负载蛋白药物的GelMA微球、制备方法及其应用 | |
| Bronzino et al. | Interstitial Transport in the Brain: Principles for Local Drug Delivery | |
| AU2011203100A1 (en) | Magnetically controllable drug and gene delivery stents |